(19)
(11) EP 1 950 307 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.02.2016 Bulletin 2016/08

(45) Mention of the grant of the patent:
23.12.2015 Bulletin 2015/52

(21) Application number: 06822478.1

(22) Date of filing: 27.10.2006
(51) International Patent Classification (IPC): 
C12N 15/867(2006.01)
A61K 38/00(2006.01)
A61P 11/00(2006.01)
C12N 5/071(2010.01)
C07K 14/47(2006.01)
 A61K 35/76(2015.01)
A61K 48/00(2006.01)
C12N 5/10(2006.01)
C12N 15/86(2006.01)
A61K 38/17(2006.01)
(86) International application number:
PCT/JP2006/321517
(87) International publication number:
WO 2007/049752 (03.05.2007 Gazette 2007/18)

(54)

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS SPIKE PROTEIN

GENTRANSFER IN LUFTWEGEPITHELSTAMMZELLE UNTER VERWENDUNG EINES MIT RNA-VIRUS-SPIKE-PROTEIN PSEUDOTYPISIERTEN LENTIVIRUSVEKTORS

TRANSFERT D'UN GÈNE DANS DES CELLULES SOUCHES ÉPITHÉLIALES DES VOIES RESPIRATOIRES VIA UN VECTEUR LENTIVIRAL PSEUDOTYPE AVEC UNE PROTÉINE DE SPICULE DE VIRUS ARN

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 28.10.2005 JP 2005313971

(43) Date of publication of application:
30.07.2008 Bulletin 2008/31

(60) Divisional application:
15190286.3

(73) Proprietor: ID Pharma Co., Ltd.
Ibaraki 300-2611 (JP)

(72) Inventors:
  • MITOMO, Katsuyuki c/o ID Pharma Co., Ltd
    Ibaraki 300-2611 (JP)
  • INOUE, Makoto c/o ID Pharma Co., Ltd.
    Ibaraki 300-2611 (JP)
  • IWASAKI, Hitoshi c/o ID Pharma Co., Ltd.
    Ibaraki 300-2611 (JP)
  • HASEGAWA, Mamoru c/o ID Pharma Co., Ltd
    Ibaraki 300-2611 (JP)
  • ALTON, Eric W
    London SW3 6LR (GB)
  • GRIESENBACH, Uta
    London SW3 6LR (GB)

(74) Representative: MacLean, Martin Robert 
Mathys & Squire LLP
The Shard 32 London Bridge Street London SE1 9SG
The Shard 32 London Bridge Street London SE1 9SG (GB)


(56) References cited: : 
WO-A1-01/92508
 WO-A2-01/32898
   
  • MITOMO ET AL: "355. Towards Cystic Fibrosis and Airway Gene Therapy: Evaluation of EGFP Gene Expression in Murine Nasal Airways Mediated by Simian Immunodeficiency Virus Vectors Pseudotyped with Sendai Virus Glycoproteins F and HN" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 11, 15 August 2005 (2005-08-15), page 139, XP005015694 ISSN: 1525-0016
  • KOBINGER G P ET AL: "Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo." NATURE BIOTECHNOLOGY MAR 2001 LNKD- PUBMED:11231554, vol. 19, no. 3, March 2001 (2001-03), pages 225-230, XP002593652 ISSN: 1087-0156
  • SINN PATRICK L ET AL: "Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer" JOURNAL OF VIROLOGY, vol. 79, no. 20, 1 October 2005 (2005-10-01), pages 12818-12827, XP002593653 ISSN: 0022-538X
  • YONEMITSU Y ET AL: "Efficient gene transfer to airway epithelium using recombinant Sendai virus" NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/79463, vol. 18, no. 9, 1 September 2000 (2000-09-01), pages 970-973, XP002165781 ISSN: 1087-0156
  • COPRENI E ET AL: "Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis." GENE THERAPY OCT 2004 LNKD- PUBMED:15454960, vol. 11 Suppl 1, October 2004 (2004-10), pages S67-S75, XP002593654 ISSN: 0969-7128
  • KLINK D ET AL: "Gene delivery systems-gene therapy vectors for cystic fibrosis" JOURNAL OF CYSTIC FIBROSIS, ELSEVIER LNKD- DOI:10.1016/J.JCF.2004.05.042, vol. 3, 1 August 2004 (2004-08-01), pages 203-212, XP004556460 ISSN: 1569-1993
  • ASANO T ET AL: "Highly efficient gene transfer into primate embryonic stem cell with a simian lentivirus vector" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US LNKD- DOI:10.1006/MTHE.2002.0655, vol. 6, no. 2, 1 August 2002 (2002-08-01), pages 162-167, XP002956700 ISSN: 1525-0016
  • SCHNELL T ET AL: "DEVELOPMENT OF A SELF-INACTIVATING, MINIMAL LENTIVIRUS VECTOR BASEDON SIMIAN IMMUNODEFICIENCY VIRUS" HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US LNKD- DOI:10.1089/10430340050015905, vol. 11, 1 January 2000 (2000-01-01), pages 439-447, XP000916370 ISSN: 1043-0342
  • KOBAYASHI M. ET AL: 'Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus' JOURNAL OF VIROLOGY vol. 77, no. 4, 2003, pages 2607 - 2614, XP003011975
  • MITOMO K. ET AL: 'Sendai Virus no Totanpakushitsu F, HN ni yotte Pseudotype-ka shita Saru Men'eki Fuzen Virus Vector wa Kikokei Soshiki ni Idenshi o Donyu dekiru' JAPANESE SOCIETY FOR VIROLOGY vol. 52, 2004, SHOROKUSHU, pages 377 - 3E16, XP003011976
  • KOEHLER D.R. ET AL: 'Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia' PROC. NATL. ACAD. SCI. USA vol. 100, no. 26, 2003, pages 15364 - 15369, XP003011977
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).